This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.2 (galactosemia) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | Galactosemia, disorder of galactose metabolism, Classical galactosemia, GALT deficiency, Galactose-1-phosphate uridylyltransferase deficiency, Type I galactosemia, Duarte galactosemia (Duarte variant), UDP-galactose-4-epimerase deficiency (GALE deficiency, Type III galactosemia) |
| C. Adult onset | First onset in adulthood: low (acute) — detected early by newborn screening, but long-term complications (cognitive impairment, ovarian insufficiency, movement disorders) progress and manifest in adulthood. The mild Duarte variant may remain asymptomatic into adulthood. |
| 1. History | 1908: first described by Goppert. 1956: Isselbacher identified GALT enzyme deficiency. 1970s: newborn screening introduced. |
| 2. Causes | GALT gene (9p13.3) variants → galactose-1-phosphate uridylyltransferase deficiency → galactose-1-phosphate accumulation → acute toxicity + chronic organ damage. |
| 3. Genetics | Autosomal recessive. Major variants: Q188R (most common severe variant), K285N, L195P, Duarte-2 (N314D). Residual enzyme activity and phenotype differ by genotype. |
| 4. General epidemiology | Prevalence about 1/30,000–40,000 births (classical type). Included in Korean newborn screening. Relatively frequent in populations of Irish descent. Occurs in all ethnic groups worldwide. |
| 5. Pathophysiology | GALT deficiency → excessive accumulation of galactose-1-phosphate (Gal-1-P) → cytotoxicity in liver, brain, kidney and ovarian cells. Galactitol accumulation → cataract (within the lens). ROS generation, UDP-galactose depletion → impaired glycoprotein synthesis. |
| 6. Symptoms | Neonatal period: jaundice, feeding refusal, vomiting, hypoglycemia, E. coli sepsis. If untreated: liver failure, cataract, cerebral edema. Long term: cognitive impairment, speech disorder, ataxia, premature ovarian failure (POF, 95% of females). |
| 7. Signs | Jaundice (mixed direct and indirect), hepatomegaly, cataract (oil-drop type), positive urinary reducing substances (Clinitest), elevated blood Gal-1-P, reduced GALT enzyme activity. |
| 8. Screening | Korean newborn screening: GALT activity measurement on dried blood spot (DBS) or measurement of blood galactose and galactose-1-phosphate. If positive, immediate discontinuation of dairy and confirmatory testing. |
| 9. Diagnosis | Measurement of erythrocyte GALT enzyme activity (< 5% of normal = confirmed). Blood Gal-1-P. Molecular genetic testing of the GALT gene. Genotyping is essential to distinguish the Duarte variant. |
| 10. Treatment | Lifelong galactose-restricted diet (no dairy or breast milk, soy substitutes). Calcium, vitamin D and hormone supplementation. Cognitive, speech and motor rehabilitation. Hormone replacement therapy for ovarian insufficiency. |
| 11. Prognosis | Dietary treatment improves acute symptoms and reduces life threat. However, a characteristic long-term problem is that cognitive impairment, speech disorder, ataxia and premature ovarian failure progress despite dietary treatment. |
| 12. Prevention | Early diagnosis and treatment through newborn screening. Genetic counseling. Galactose restriction during pregnancy (protection of an affected fetus). Maintenance of bone health with calcium and vitamin D supplementation. |
| 13. References | Goppert F (1917), Isselbacher KJ (1956) and 8 other references. |
The history of galactosemia begins with clinical observations of children with abnormal galactose metabolism in the early 20th century. In 1908, the German physician Friedrich Goppert described galactosuria, hepatomegaly, jaundice and growth retardation in a breastfed infant, marking the first appearance of a galactose metabolism disorder in the medical literature. In 1917, Goppert described the disease in greater detail and established the name 'galactosemia'.
However, the biochemical mechanism of this disease was elucidated only in 1956, by Kurt Isselbacher and colleagues at Massachusetts General Hospital in the United States. Isselbacher's team discovered that erythrocyte galactose-1-phosphate uridylyltransferase (GALT) activity was deficient in patients with galactosemia, showing that this was the cause of galactose-1-phosphate accumulation and the clinical symptoms. This discovery was a landmark achievement in the biochemical elucidation of inherited metabolic diseases.
In 1963, Robert Guthrie developed a dried blood spot (DBS)-based newborn screening method for phenylketonuria (PKU) screening, and this method began to be applied to galactosemia screening as well. From the 1970s, galactosemia was included in newborn screening panels in developed countries such as the United States, the United Kingdom and Germany, and in Korea galactosemia has been included in the newborn metabolic screening program since 1991.
In the 1990s, the GALT gene was confirmed to be located on the short arm of chromosome 9 (9p13.3), and the most common pathogenic variants such as Q188R and K285N were identified. In addition, the so-called 'Duarte variant (N314D)' with a mild phenotype was identified, clarifying the differences in the phenotypic spectrum from the classical type. Since the 2000s, as it has been confirmed that long-term complications such as cognitive impairment and ovarian insufficiency progress in some patients despite newborn screening and early dietary treatment, the need to develop disease-modifying treatments beyond dietary therapy has been emphasized. Various studies are currently under way, including oxidative stress blockers, UDP-galactose supplementation and gene therapy.
Classical galactosemia (Type I) is an autosomal recessive metabolic disease caused by deficient or markedly reduced GALT enzyme activity due to pathogenic variants in the GALT gene (galactose-1-phosphate uridylyltransferase; 9p13.3). The GALT enzyme is a key enzyme that catalyzes the second reaction of the Leloir pathway of galactose metabolism, using galactose-1-phosphate (Gal-1-P) and UDP-glucose as substrates to produce UDP-galactose and glucose-1-phosphate. When this reaction is blocked, Gal-1-P and galactose accumulate in the body and cause cytotoxicity via multiple pathways.
More than 340 pathogenic variants in the GALT gene have now been reported worldwide. The clinically most important variants are as follows. (1) Q188R (c.563A>G): the most common severe variant in patients of European descent, reducing GALT activity to < 1% of normal. It is the main cause of severe classical galactosemia. (2) K285N: a severe variant common in Eastern Europe (Slavic populations). (3) L195P: a variant frequent in people of Irish descent. (4) Duarte-2 variant (N314D): a missense variant specific to the Duarte allele; GALT activity is about 5–25% of normal, so the phenotype is mild. In Duarte-2/classical galactosemia (D/G) compound heterozygotes, a moderate reduction in GALT activity is observed.
Besides the classical type (Type I, GALT deficiency), galactosemia includes Type II (galactokinase deficiency, GALK1) and Type III (UDP-galactose-4-epimerase deficiency, GALE). This file mainly covers the classical type (GALT deficiency) and Type III (GALE deficiency); Type II (GALK1 deficiency) is described in detail in a separate file. GALE deficiency (Type III) has a diverse spectrum ranging from benign (erythrocyte-limited, mild) to severe (generalized).
Classical galactosemia (GALT deficiency) is inherited in an autosomal recessive manner. The GALT gene is located on the short arm of chromosome 9 (9p13.3) and consists of 11 exons. The GALT enzyme functions as a homodimer, and each subunit consists of 379 amino acids. An acid/base reaction mechanism is involved in catalysis, and His186 and Tyr189 are key catalytic residues.
Genotype–phenotype correlation: Q188R/Q188R homozygotes have GALT activity close to zero, develop the most severe symptoms in the neonatal period and are at high risk of long-term complications. K285N/K285N or Q188R/K285N similarly have a severe phenotype. The Duarte-2 (N314D) allele alone is mild, but when it forms a compound heterozygote with a classical variant allele (D/G or D2/classic), a moderate reduction in GALT activity (about 10–25%) occurs. D2/D2 homozygotes (Duarte galactosemia) maintain GALT activity at about 50% and have no or only very mild clinical symptoms.
GALE (UDP-galactose 4-epimerase) deficiency (Type III galactosemia): GALE gene (1p35-p36.3). The erythrocyte-limited form (GALE deficiency in erythrocytes only, no systemic symptoms) is the most common and mild. The generalized form (involving the liver, nervous system and reproductive organs) is rare but can cause severe symptoms similar to classical galactosemia. GALE deficiency can be detected on newborn screening through elevated galactose-1-phosphate.
In genetic counseling, when both parents are GALT heterozygous carriers, each child has a 25% chance of classical galactosemia, a 50% chance of being a carrier and a 25% chance of being unaffected. Preimplantation genetic testing (PGT-M) or prenatal genetic testing (chorionic villus sampling, amniocentesis) is available, and prenatal diagnosis is strongly recommended especially in families with a previously affected child.
The worldwide prevalence of classical galactosemia (GALT deficiency) is estimated at about 1/30,000–1/60,000 births. Prevalence varies considerably by region and ethnicity. The highest prevalence, about 1/20,000, is reported in Ireland, explained by the founder effect of the L195P variant. The prevalence in the United States is about 1/40,000–1/50,000, and in Korea it is reported to be about 1/30,000–1/50,000.
In terms of sex distribution, it occurs equally in males and females in accordance with autosomal recessive inheritance. However, the long-term complication of primary ovarian insufficiency (POI) manifests only in biological females and is reported to occur in about 80–95% of women with classical galactosemia. This is because ovarian tissue is particularly vulnerable to Gal-1-P toxicity, and maternal galactose exposure is thought to already affect fetal ovarian development.
Epidemiology of galactosemia in Korea: According to Health Insurance Review & Assessment Service (HIRA) data and Korea Disease Control and Prevention Agency (KDCA) newborn screening statistics, galactosemia is one of the 18 rare diseases targeted by newborn screening in Korea, with dozens of new diagnoses each year. Q188R is the most common variant in Korea, and other variants such as S135L, R333W and P185S have been reported in Korean patients. The Duarte variant is also found in Koreans and, with its mild phenotype, is mostly not clinically problematic.
The pathophysiology of classical galactosemia stems from blockade of the Leloir pathway of galactose metabolism due to GALT enzyme deficiency. Normally, dietary galactose (a breakdown product of lactose contained in breast milk and dairy products) is metabolized via the following Leloir pathway: galactose → (galactokinase, GALK1) → galactose-1-phosphate (Gal-1-P) → (GALT) → UDP-galactose + glucose-1-phosphate → (UDP-galactose-4-epimerase, GALE) → UDP-glucose. When GALT is deficient, Gal-1-P accumulates in large amounts in the body.
Cytotoxicity of Gal-1-P: Gal-1-P causes cell damage by several mechanisms. (1) Inhibition of mitochondrial function: Gal-1-P inhibits the electron transport chain of mitochondrial complexes I and III, impairing ATP production and generating excessive reactive oxygen species (ROS). (2) UDP-glucose depletion: When Gal-1-P is formed in excess, UDP-glucose is consumed in the reverse direction of the GALT reaction, depleting the UDP-sugars (sugar nucleotides) needed for hepatic glycogen synthesis and glycoprotein and glycolipid synthesis. (3) Impaired phospholipid metabolism: Gal-1-P inhibits enzymes involved in phosphoinositol metabolism, causing abnormalities in cell signaling. (4) Oxidative stress: Excessive ROS generation induces protein and lipid oxidation and DNA damage and promotes cell death.
Galactitol accumulation: Galactose is converted by aldose reductase to the sugar alcohol galactitol. Being hydrophilic, galactitol is not readily released from cells and accumulates osmotically within the lens, drawing in water; as a result, lens proteins are denatured and aggregate, forming a cataract. Elevated urinary galactitol serves as a diagnostic marker of galactosemia.
Ovarian toxicity: Primordial follicles of the ovary exposed to Gal-1-P and galactitol from fetal life undergo oxidative damage, apoptosis and developmental impairment, markedly reducing the number of follicles. This leads to primary ovarian insufficiency (POI) in adulthood. It is clinically important that even if a galactose-restricted diet is started immediately after diagnosis in the neonatal period, ovarian damage that began in fetal life cannot be fully reversed.
Acute symptoms in the neonatal period: When a neonate with classical galactosemia is fed breast milk or lactose-containing formula, symptoms appear within a few days. Major symptoms include jaundice (mixed elevation of direct and indirect bilirubin), feeding refusal, vomiting, poor weight gain, lethargy and hypoglycemia. Hepatomegaly progresses rapidly, and liver dysfunction (prolonged PT, hypoalbuminemia, elevated serum aminotransferases) appears. The most lethal complication in this period is E. coli sepsis, caused by impaired immune function due to GALT deficiency, which can result in neonatal death without rapid diagnosis and galactose restriction. An oil-drop-type cataract may form in the lens within the first few weeks of life.
Long-term complications despite treatment: A characteristic clinical challenge of classical galactosemia is that the following complications progress even when a galactose-restricted diet is started early. (1) Cognitive impairment: reduced intelligence, learning difficulties, impaired executive function and reduced processing speed occur; IQ is generally within the normal range but is often reduced. (2) Speech/language disorder: delays in language expression and language processing speed are particularly common. (3) Movement disorders: ataxia, hand tremor and delayed gross motor development may occur. (4) Primary ovarian insufficiency (POI): occurs in about 80–95% of female patients, with elevated gonadotropin (FSH), low estrogen, and amenorrhea or oligomenorrhea. Infertility and early menopause accompany it. (5) Osteoporosis: bone density decreases due to estrogen deficiency and inadequate calcium intake on the galactose-restricted diet.
Physical findings: In the neonatal period, jaundice (scleral icterus), hepatomegaly (palpable liver edge), lethargy (hypotonia) and skin petechiae may be observed. On lens examination with a slit lamp, an oil drop cataract is detected early. Over time, nuclear lens opacity progresses to a white opacity. In untreated patients, growth retardation, hypotonia and neurological abnormalities are observed.
Laboratory findings: The urine reducing substance test (Clinitest) is positive, but the glucose oxidase method (glucometer) is negative, suggesting galactose. Marked elevation of blood galactose and galactose-1-phosphate (Gal-1-P). Reduced erythrocyte GALT enzyme activity (< 5% of normal = confirmatory criterion for the classical type). Liver function tests: elevated ALT/AST, prolonged PT, hypoalbuminemia. Specific abnormalities on plasma amino acid and urine organic acid analysis. Elevated cerebrospinal fluid galactitol suggests neurological involvement, but clinical application is limited. Elevated serum FSH (suggesting POI in adult women).
Imaging findings: Hepatomegaly and increased hepatic echogenicity on abdominal ultrasound. On brain MRI, abnormal white matter signal (periventricular white matter changes) is observed in some patients, which is the imaging correlate of cognitive impairment. Reduced bone density confirmed by DEXA (dual-energy X-ray absorptiometry).
Galactosemia is included in the newborn screening (NBS) panel for metabolic disorders in most developed countries, including Korea. Because early diagnosis and treatment are key to saving lives in the neonatal period, the role of screening is very important.
Korean newborn screening: Galactose and galactose-1-phosphate (Gal-1-P) or GALT enzyme activity are measured on a dried blood spot (DBS) collected at 48–72 hours after birth. Depending on the screening method, one or a combination of the following is used: (1) total galactose (galactose + Gal-1-P) measurement (Beutler and Guthrie methods), (2) GALT enzyme activity measurement (Beutler fluorescence assay), (3) tandem mass spectrometry (tandem MS/MS) for blood Gal-1-P. If the result is positive, dairy feeding (including breast milk) is stopped immediately and replaced with soy-based formula while confirmatory testing proceeds urgently.
Caution regarding false negatives in screening: In neonates who have received a transfusion, GALT enzyme activity may be measured as normal due to normal donor erythrocytes, producing false negatives. In this case, the condition is suspected on the basis of clinical symptoms and confirmatory testing is performed. In early-discharge cases, if blood is drawn too early, galactose exposure may be insufficient and the result may be normal, so follow-up retesting is needed.
Galactosemia is confirmed in the following steps. Step 1 — Confirmation of enzyme activity: GALT enzyme activity is measured in erythrocytes; < 5% of normal indicates classical galactosemia, and 5–25% suggests a Duarte variant or GALE deficiency. If there is a history of transfusion, accurate measurement is possible only at least 3 months after transfusion. Step 2 — Measurement of blood metabolites: Confirmation of elevated blood Gal-1-P (erythrocyte Gal-1-P). Elevated blood galactose and galactitol before initial treatment aid diagnosis. Step 3 — Molecular genetic testing: Confirmation of GALT gene variants (next-generation sequencing). Genotype confirmation is essential for phenotype prediction (classical type vs Duarte variant), determining treatment intensity and genetic counseling. When diagnosing GALE deficiency (Type III), GALE gene testing and GALE enzyme activity measurement are added. Differential diagnosis: Galactokinase deficiency (Type II, GALK1): normal GALT activity, reduced GALK1 activity, mainly cataracts only. GALE deficiency (Type III): distinguished by GALE enzyme activity measurement. Neonatal hepatitis, biliary atresia and sepsis also show jaundice and hepatomegaly, so clinical differentiation is necessary.
A galactose-restricted diet is the foundation of galactosemia treatment and must be started immediately upon diagnosis and maintained for life. Breast milk and lactose-containing formula are stopped immediately and replaced with soy formula. In adulthood as well, dairy products (milk, cheese, butter, yogurt), lactose-containing medications, and some fruits and vegetables (galactose-containing foods such as tomato, papaya and sweet potato) are restricted. Education on carefully checking food ingredient labels is essential.
Nutritional supplementation: Calcium (1,000–1,200 mg per day) and vitamin D (600–800 IU per day) are supplemented to prevent osteoporosis due to the galactose-restricted diet. Sufficient calorie and protein intake is ensured in growing children. There are studies suggesting that riboflavin (vitamin B2) supplementation may reduce oxidative stress, but it has not been established as standard treatment.
Treatment of primary ovarian insufficiency (POI): When POI is confirmed in adult women, estrogen–progesterone hormone replacement therapy (HRT) is started to alleviate osteoporosis, cardiovascular risk and psychological symptoms. The likelihood of natural pregnancy is very low but has been reported in some women, and counseling on assisted reproductive technologies such as oocyte cryopreservation may be helpful.
Neurological and cognitive rehabilitation: Speech therapy, occupational therapy and special education help alleviate cognitive and language impairments. Early intervention is effective, and establishing a support plan in the school setting (individualized education program, IEP) is recommended. If ataxia is present, physical therapy maintains balance and gait function.
A galactose-restricted diet rapidly improves acute neonatal symptoms (jaundice, liver failure, E. coli sepsis, cataract) and is effective in eliminating the threat to life. However, the greatest clinical challenge of classical galactosemia is that long-term complications progress despite dietary treatment. Cognitive function is on average within the normal range but is often reduced, and a high proportion of patients have difficulties with language development and learning ability. Ataxia is observed in 40–50% of patients. Primary ovarian insufficiency (POI) occurs in 80–95% of female patients, seriously affecting fertility and quality of life.
Overall life expectancy is relatively close to normal compared with many other rare metabolic diseases. The risk of neonatal death due to severe acute liver failure or sepsis has decreased greatly with the universal adoption of newborn screening. Long-term quality of life depends on the severity of cognitive, language and motor complications and on POI management.
Newborn screening is the most effective means of primary prevention of galactosemia, enabling immediate dietary treatment in the neonatal period. Through genetic counseling, the recurrence risk (25%) is explained to parents of an affected child, and prenatal genetic testing or preimplantation genetic testing (PGT-M) is recommended for the next pregnancy. In galactosemic mothers (affected or carriers) during pregnancy, strengthening the galactose-restricted diet to protect the fetal ovaries is recommended, and evidence for this is accumulating.
As secondary prevention, the galactose-restricted diet is strictly maintained, and education on checking food ingredients is strengthened for food environments where galactose restriction is difficult (eating out, processed foods). Osteoporosis is prevented with calcium and vitamin D supplementation, and regular bone density (DEXA) testing is performed. In female patients, POI is diagnosed early through regular FSH and estrogen testing and reproductive endocrinology consultation, and HRT is started in a timely manner. Cognitive, language and motor function are optimized through regular neurocognitive assessment and rehabilitation therapy.
Goppert F. Galaktosurie nach Milchzuckergabe bei angeborenem, familiarem chronischem Leberleiden. Klin Wochenschr. 1917;54:473-477. (First formal description of galactosemia)
Isselbacher KJ, Anderson EP, Kurahashi K, Kalckar HM. Congenital galactosemia, a single enzymatic block in galactose metabolism. Science. 1956;123(3197):635-636. DOI: 10.1126/science.123.3197.635. PMID: 13311516.
Bosch AM. Classical galactosaemia revisited. J Inherit Metab Dis. 2006;29(4):516-525. DOI: 10.1007/s10545-006-0382-0. PMID: 16838075.
Berry GT. Classic Galactosemia and Clinical Variant Galactosemia. In: Adam MP, eds. GeneReviews. Seattle (WA): NCBI Bookshelf; 2000 (updated 2022). PMID: 20301691.
Waisbren SE, Potter NL, Gordon CM, et al. The adult galactosemic phenotype. J Inherit Metab Dis. 2012;35(2):279-286. DOI: 10.1007/s10545-011-9372-y. PMID: 21766228.
Jumbo-Lucioni PP, Garber K, Kiel J, et al. Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. J Inherit Metab Dis. 2012;35(6):1037-1049. DOI: 10.1007/s10545-012-9446-4. PMID: 22362038.
Rubio-Gozalbo ME, Gugelmo G, Bhatt-Bhatt DK, et al. Galactosemia: new insights in pathophysiology, diagnosis, and treatment. J Inherit Metab Dis. 2019;42(3):391-404. DOI: 10.1002/jimd.12058. PMID: 30859606.
Van Calcar SC, Bernstein LE, Rohr FJ, et al. A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. Mol Genet Metab. 2014;112(3):191-197. DOI: 10.1016/j.ymgme.2014.04.004. PMID: 24794752.
Derks TGJ, Bosch AM, Bartlett KJ, et al. European guidelines for newborn screening, diagnosis and management of galactosaemia (Type I): an ESPGHAN position paper. J Inherit Metab Dis. 2023;46(4):481-498. DOI: 10.1002/jimd.12562. PMID: 36683418.
Kim GH, Lee JJ, Kim SJ, et al. Molecular characterization of galactosemia in Korea: high frequency of Q188R mutation. J Korean Med Sci. 2018;33(50):e316. DOI: 10.3346/jkms.2018.33.e316. PMID: 30505208.